Schizoaffective Disorder News and Research

RSS
Early natural history of bipolar disorder mapped

Early natural history of bipolar disorder mapped

Gray matter changes reflect psychosis burden

Gray matter changes reflect psychosis burden

Novel approach confirms dysfunctional energy production in schizophrenia

Novel approach confirms dysfunctional energy production in schizophrenia

Mood disorder subtypes remain in the family

Mood disorder subtypes remain in the family

Reviva announces successful completion of End-of-Phase 2 meeting for RP5063 drug

Reviva announces successful completion of End-of-Phase 2 meeting for RP5063 drug

Left-handers more likely to suffer from psychotic disorders

Left-handers more likely to suffer from psychotic disorders

Psychosis prediction model could facilitate early intervention

Psychosis prediction model could facilitate early intervention

Cash rewards encourage antipsychotic injection adherence

Cash rewards encourage antipsychotic injection adherence

Kraepelin distinctions back in favor

Kraepelin distinctions back in favor

Genetic score backs schizophrenia spectrum

Genetic score backs schizophrenia spectrum

Weekend reading: Mental illness stigma, health insurance mazes and female libido

Weekend reading: Mental illness stigma, health insurance mazes and female libido

REFRESH study: RP5063 shows promise for schizophrenia and schizoaffective disorder

REFRESH study: RP5063 shows promise for schizophrenia and schizoaffective disorder

Treating substance abuse alone helps patients with co-occurring psychosis

Treating substance abuse alone helps patients with co-occurring psychosis

Foreign-born adoptees most at risk for psychiatric disorders

Foreign-born adoptees most at risk for psychiatric disorders

Social cognition and negative symptoms scores reveal schizophrenia subgroups

Social cognition and negative symptoms scores reveal schizophrenia subgroups

Family members with rare gene mutation at high risk of developing schizophrenia

Family members with rare gene mutation at high risk of developing schizophrenia

Reviva Pharmaceuticals completes enrollment in RP5063 phase 2 trial for schizophrenia

Reviva Pharmaceuticals completes enrollment in RP5063 phase 2 trial for schizophrenia

Metabolic syndrome linked to poorer cognition in schizophrenia

Metabolic syndrome linked to poorer cognition in schizophrenia

People in creative professions are treated more often for mental illness

People in creative professions are treated more often for mental illness

Maternal obstetric problems linked to schizophrenia risk

Maternal obstetric problems linked to schizophrenia risk